NCT07398599 2026-02-10
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
Second Affiliated Hospital of Nanchang University
Phase NA Recruiting
Second Affiliated Hospital of Nanchang University
Ruijin Hospital
Memorial Sloan Kettering Cancer Center